Enantioselective acylation of 2-hydroxymethyl-2,3-dihydrobenzofurans catalysed by lipase from Pseudomonas cepacia (Amano PS) and total stereoselective synthesis of (−)-(R)-MEM-protected arthrographol
摘要:
Lipase Amano PS catalysed acylation of (+/-)-2-hydroxymethyl-2,3-dihydrobenzofurans using vinyl acetate as the acyl donor in n-hexane gave (-)-(R)-2-acetoxymethyl-2,3-dihydrobenzo and (+)-(S)-2-hydroxymethyl-2,3-dihydrobenzofurans in high enantiomeric excess. (-)-(R)-Acetate 18j is converted to (-)-(R)-MEM-protected arthrographol 22. (C) 2000 Published by Elsevier Science Ltd.
[EN] INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP)<br/>[FR] INHIBITEURS DE LA PROTÉINE DE LIAISON AUX ACIDES GRAS (FABP)
申请人:SCHERING CORP
公开号:WO2010056631A1
公开(公告)日:2010-05-20
The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein ("FABP") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)
Double isomerization/cycloisomerization/aromatization of 1-(allyloxy)-2-(cyclopropylmethyl)benzenes to give 2-ethyl-3-isopropylbenzofurans using a multitasking single rhodium catalyst
reaction vessel are important for the development of eco-compatible chemistry. Here, we have developed a rhodium-catalyzed system that transforms 1-(allyloxy)-2-(cyclopropylmethyl)benzene derivatives to 2-ethyl-3-isopropylbenzofurans via double isomerization/cycloisomerization/aromatization.
A New and Facile Synthesis of Chroman-3-ols, 3,4-Dihydro-2H-[1]-Benzopyran-3-ols
作者:V. Satyanarayana、Ch. Prasad Rao、G. L. David Krupadanam、G. Srimannarayana
DOI:10.1080/00397919108016418
日期:1991.7
Abstract o-Allylphenols react with m-chloroperoxybenzoic acid (m-CPBA) in dry chloroform to give chroman-3-ols in a single step in good yields (93–96%).
The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)